CellCentric
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
$220MSeries D
Role not disclosedHH
HBM Healthcare
Activity from announced rounds
Activity in this selectionepisode1-ventures-13603d62
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $525M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionParabilis Medicines
Develops medicines targeting historically undruggable protein targets in cancer
$305MSeries F
Role not disclosed